Indian J Pharm Close
 

Figure 3: (a) Correlation of Psoriasis Area Severity Index score with quality of life in Group A (n = 52): topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]). r = 0.07 (little or no correlation between Psoriasis Area Severity Index and quality of life). (b) Correlation of Psoriasis Area Severity Index score with quality of life in Group B (n = 32): methotrexate + topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]). r = 0.29 (weak positive correlation between Psoriasis Area Severity Index and quality of life). (c) Correlation of Psoriasis Area Severity Index score with quality of life in Group C (n = 30): cyclosporine + topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]). r = 0.13 (weak positive correlation between Psoriasis Area Severity Index and quality of life)

Figure 3: (a) Correlation of Psoriasis Area Severity Index score with quality of life in Group A (<i>n</i> = 52): topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]). <i>r</i> = 0.07 (little or no correlation between Psoriasis Area Severity Index and quality of life). (b) Correlation of Psoriasis Area Severity Index score with quality of life in Group B (<i>n</i> = 32): methotrexate + topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]). <i>r</i> = 0.29 (weak positive correlation between Psoriasis Area Severity Index and quality of life). (c) Correlation of Psoriasis Area Severity Index score with quality of life in Group C (<i>n</i> = 30): cyclosporine + topical treatment (betamethasone valerate and [clobetasol propionate + salicylic acid]). <i>r</i> = 0.13 (weak positive correlation between Psoriasis Area Severity Index and quality of life)